Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Henlius, Sandoz Broaden Biosimilar Tie-Up Deal For Up To 10 Products

17 August 2026 · By · Wire by Fusion42

Published

17 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 17 August 2026 · Fusion42 review

Henlius and Sandoz have expanded their biosimilar collaboration deal to cover up to 10 products, broadening their partnership in the biopharmaceutical sector.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

This biosimilar deal expansion opens a path to scale biosimilar portfolios in China and beyond. Biotech founders in biosimilars now face quicker routes to market and should explore partnerships with global firms like Sandoz.

◆ Coverage

3 sources · 17 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiosimilarspartnershipbiotechpharmachina